Lincocin: Potent Gram-Positive Bacterial Infection Treatment
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $7.54 | $75.36 (0%) | 🛒 Add to cart |
| 20 | $7.03 | $150.73 $140.68 (7%) | 🛒 Add to cart |
| 30 | $6.33 | $226.09 $189.92 (16%) | 🛒 Add to cart |
| 60 | $4.42 | $452.19 $265.28 (41%) | 🛒 Add to cart |
| 90 | $4.22 | $678.28 $379.84 (44%) | 🛒 Add to cart |
| 120 | $4.02 | $904.37 $482.33 (47%) | 🛒 Add to cart |
| 180 | $3.72 | $1356.56 $669.23 (51%) | 🛒 Add to cart |
| 270 | $3.42 | $2034.83 $922.46 (55%) | 🛒 Add to cart |
| 360 | $3.01
Best per pill | $2713.11 $1085.25 (60%) | 🛒 Add to cart |
Synonyms | |||
Lincocin, with the active ingredient lincomycin hydrochloride, is a lincosamide antibiotic specifically formulated to combat serious infections caused by susceptible strains of gram-positive bacteria. It is a critical therapeutic agent in clinical settings where penicillin is not suitable, offering a targeted approach to managing anaerobic and aerobic infections. Its formulation ensures reliable bioavailability and a focused spectrum of activity, making it a valuable tool for healthcare professionals in hospital and clinical practice.
Features
- Active ingredient: Lincomycin hydrochloride
- Available in injectable forms: 2 mg/mL and 10 mg/mL concentrations
- Specifically targets gram-positive aerobic bacteria and anaerobic organisms
- Demonstrated stability in solution under recommended storage conditions
- Manufactured under strict pharmaceutical quality control standards
Benefits
- Provides effective treatment for severe infections when penicillin is not an appropriate option
- Rapid onset of action helps control infection progression and reduce bacterial load
- Targeted spectrum minimizes disruption to normal gut flora compared to broad-spectrum antibiotics
- Flexible dosing regimens allow for tailored treatment based on infection severity and patient factors
- Well-established efficacy profile in both hospital and outpatient settings
- Proven clinical success in treating bone and joint infections, respiratory tract infections, and septicemia
Common use
Lincocin is primarily indicated for the treatment of serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci. It is particularly valuable in cases of penicillin allergy or when the causative organisms are resistant to other antimicrobial agents. Common clinical applications include treatment of respiratory tract infections, skin and soft tissue infections, septicemia, and osteomyelitis. The medication demonstrates particular efficacy against anaerobic bacteria, making it suitable for abdominal infections and pelvic inflammatory disease caused by susceptible organisms.
Dosage and direction
Dosage must be individualized based on the severity of the infection and the patient’s clinical status. For serious infections, the usual adult dosage is 600 mg intramuscularly every 12-24 hours or 600 mg to 1 gram intravenously every 8-12 hours. For more severe infections, 1 gram intravenously every 8 hours may be required. Pediatric dosage is based on body weight at 10 mg/kg intramuscularly every 12-24 hours or 10-20 mg/kg intravenously every 8-12 hours. Intravenous administration should be diluted in appropriate solutions and infused over at least 60 minutes. Treatment should continue for at least 10 days in beta-hemolytic streptococcal infections to prevent rheumatic fever or glomerulonephritis.
Precautions
Lincocin should be used with caution in patients with a history of gastrointestinal disease, particularly colitis. Renal and hepatic function should be monitored during extended therapy. Use with caution in patients with asthma or significant allergies. Diarrhea may indicate antibiotic-associated colitis and may require discontinuation. Blood counts and liver function tests are recommended during prolonged therapy. Caution should be exercised when administering to newborns due to immature organ systems. Patients should be advised to report any signs of superinfection or unusual symptoms promptly.
Contraindications
Lincocin is contraindicated in patients with known hypersensitivity to lincomycin, clindamycin, or any component of the formulation. It should not be used in patients with a history of antibiotic-associated colitis, regional enteritis, or ulcerative colitis. Contraindicated in patients with meningitis as penetration into cerebrospinal fluid is poor. Should not be administered to patients with severe hepatic impairment without careful monitoring and dosage adjustment.
Possible side effect
Common side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. More serious side effects may include pseudomembranous colitis, which can be severe and potentially fatal. Hematologic effects such as neutropenia, leukopenia, agranulocytosis, and thrombocytopenia have been reported. Allergic reactions including rash, urticaria, and anaphylaxis may occur. Hepatic dysfunction with jaundice and abnormal liver function tests has been observed. Local reactions at injection site including pain, induration, and sterile abscess may occur with intramuscular administration.
Drug interaction
Concurrent use with neuromuscular blocking agents may enhance neuromuscular blockade. Antagonism has been demonstrated between Lincocin and erythromycin. May reduce the effectiveness of oral contraceptives; additional contraceptive measures should be used. Caution should be exercised when administering with other potentially ototoxic or nephrotoxic drugs. Interaction with opioid analgesics may increase the risk of constipation and ileus. May potentiate the effects of warfarin and other oral anticoagulants.
Missed dose
If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Doubling of doses is not recommended. Maintaining consistent antibiotic levels is important for therapeutic efficacy, so patients should be advised to adhere strictly to the prescribed dosing schedule. Healthcare providers should be notified of any missed doses, particularly in hospital settings where therapeutic drug monitoring may be necessary.
Overdose
Symptoms of overdose may include severe diarrhea, nausea, vomiting, and abdominal cramps. Neurological symptoms including dizziness and vertigo may occur. In cases of significant overdose, supportive measures should be instituted along with careful monitoring of vital signs. Hemodialysis is not effective for removing lincomycin from the bloodstream. Treatment should be symptomatic and supportive, with particular attention to maintaining fluid and electrolyte balance. There is no specific antidote for lincomycin overdose.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from light and excessive heat. Do not freeze. Keep in original container until time of use. Parenteral solutions should be used within 24 hours if stored at room temperature or within 48 hours if refrigerated. Do not use if solution is discolored or contains particulate matter. Keep out of reach of children and pets. Properly discard any unused portion according to institutional guidelines for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lincocin is a prescription medication that should only be used under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for complete information regarding indications, dosage, administration, and potential side effects. Individual patient response may vary, and therapeutic decisions should be based on professional medical judgment considering the patient’s specific clinical situation.
Reviews
Clinical studies have demonstrated Lincocin’s efficacy in treating serious gram-positive infections, with success rates exceeding 85% in appropriate patient populations. Healthcare professionals note its particular value in penicillin-allergic patients and its reliable activity against anaerobic organisms. Some clinicians report excellent results in osteomyelitis cases where other antibiotics have failed. The need for parenteral administration is noted as a limitation for outpatient therapy. Most reviews emphasize the importance of proper patient selection and monitoring for optimal outcomes while minimizing potential adverse effects.